Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Grünenthal GmbH
Woman and Man Max 99 years
Grünenthal GmbH
Update Il y a 4 ans
Open-label, single-arm, flexible dosing, Phase III trial, with oral tapentadol PR in subjects with chronic malignant tumor-related pain who have completed the Maintenance Period of the KF 5503/15 trial
The characterization of the long term safety profile of tapentadol PR at doses ranging from 100 mg to 250 mg taken twice daily, in patients with malignant tumor-related pain
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Grünenthal GmbH
Update Il y a 4 ans
A randomized Phase IIa trial evaluating the safety and efficacy of a new centrally acting analgesic in subjects with pain due to diabetic polyneuropathy
To evaluate the analgesic efficacy of GRT6005 in subjects with moderate to severe pain due to diabetic polyneuropathy
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Grünenthal GmbH
Update Il y a 4 ans
A randomized, multi-center, double-blind, parallel-group, multiple-dose study assessing the analgesic efficacy and safety of 3 different doses of GRT0151Y compared to placebo and an active comparator in adults following tonsillectomy
Compare the oral multiple-dose analgesic efficacy and safety of 3 different doses of GRT0151Y to placebo in subjects with moderate to severe postoperative pain after tonsillectomy on Day 4 and Day 5
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man
Between 18 years
and 99 years
Grünenthal GmbH
Update Il y a 4 ans
Essai de phase 3 randomisé en double aveugle évaluant l’efficacité et la tolérance du tapentadol LP chez des patients souffrant de douleurs chroniques modérées à sévères et liées à un cancer. [essai clos aux inclusions]
L’objectif de cet essai est d’évaluer l’efficacité et la tolérance du tapentadol LP chez des patients souffrant de douleurs chroniques modérées à sévères et liées à un cancer. Les patients sont répar...
Country
France
organs
Tout Cancer
Specialty
Soins de Support
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Grünenthal GmbH
Update Il y a 4 ans
An evaluation of the effectiveness and tolerability of tapentadol hydrochloride prolonged release, and tapentadol hydrochloride immediate release on demand, in subjects with severe chronic nociceptive, mixed or neuropathic low back pain taking WHO Step III analgesics but showing a lack of tolerability
Evaluate the effectiveness, tolerability, and safety of tapentadol hydrochloride PR in subjects with severe chronic nociceptive, mixed or neuropathic low back pain who are taking WHO Step III analgesi...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Grünenthal GmbH
Update Il y a 4 ans
Efficacy, safety, and tolerability of GRT6005 in subjects with moderate to severe chronic low back pain
The objective of this trial is to assess the analgesic efficacy, safety, and tolerability of once daily orally administered GRT6005 in a total of 3 fixed doses (i.e., 200 μg, 400 μg, and 600 μg GRT...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Grünenthal GmbH
Update Il y a 4 ans
Evaluation of the therapeutic effectiveness and safety of 7 days of treatment with a novel analgesic in subjects with peripheral neuropathic pain
To explore the efficacy of GRT010 oral solution on spontaneous and evoked pain in subjects with persistent moderate to severe peripheral neuropathic pain due to post-herpetic neuralgia, post-operative...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Grünenthal GmbH
Update Il y a 4 ans
Cross-over multiple dose study assessing the analgesic efficacy and safety of oral GRT9906 PR compared to active comparator and placebo in subjects with painful polyneuropathy of mixed origin
To assess the multiple-dose analgesic efficacy and safety of oral GRT9906 PR at 120-240 mg daily in comparison to placebo in subjects with painful polyneuropathy
Country
None
organs
None
Specialty
None
unknown
More information
Previous
1
2
3